UK Clinic Network Announces Arthrosamid Injections For Osteoarthritis Knee Pain

MSK Doctors founder Professor Paul Lee, MBBCh, MFSEM (UK), MSc, PhD, FEBOT (EU), FRCS (T&O), has announced that Arthrosamid gel injections are now available at many clinics within the MSK Doctors network, including MSK House Clinic in Sleaford, London Cartilage Clinic, 108 Harley Street Clinic, the Keep Clinic in Grantham, and others. A groundbreaking hydrogel treatment, Arthrosamid offers long-lasting pain relief for patients coping with knee osteoarthritis (OA), providing an alternative to invasive surgeries.

More information is available at https://mskdoctors.com/treatments/arthrosamid

Arthrosamid, also known as polyacrylamide (PAAG) hydrogel, is an advanced injectable treatment developed to improve joint function and reduce pain in patients with knee OA that has not responded to medication or physical therapy. A minimally invasive procedure, found to be more effective than hyaluronic acid injections, it is a one-time treatment performed under local anaesthesia, enabling patients to benefit from pain relief and enhanced mobility without the recovery time and complications associated with surgery.

“Knee osteoarthritis can drastically impact a person’s ability to enjoy life, limiting even the simplest activities,” says Lee. “Arthrosamid offers a new, well-evidenced treatment option for those seeking effective, long-term relief without the challenges and risks of surgery.”

The gel is injected directly into the knee joint, where it integrates with the synovial tissue to create a cushioning effect. By thickening the joint lining and improving lubrication, Arthrosamid protects against bone-on-bone contact, alleviating pain and improving mobility. Unlike corticosteroids or hyaluronic acid injections, Arthrosamid is designed for prolonged efficacy, with results lasting up to several years after a single injection.

Clinical studies support its effectiveness. A 52-week prospective study by Henning Bliddal et al. demonstrated significant improvements in knee OA symptoms, while another study by Maulana R., Cole A., and Lee P.Y.F. found reductions in patellofemoral bone marrow lesions after treatment. Patients with moderate to severe OA, particularly those who are ineligible for surgery, have reported significant improvements in daily activities post-treatment.

Lee notes, “Arthrosamid represents a breakthrough in knee osteoarthritis care. It combines advanced technology with evidence-based medicine, providing a sustainable solution for pain management and improved quality of life.”

Patients struggling with knee OA can book a consultation with an orthopaedic specialist to learn more about Arthrosamid using the MSK Doctors platform.

Visit https://mskdoctors.com for additional details.

MSK Doctors

MSK House London Road
Silk Willoughby, Sleaford, Lincolnshire
Sleaford
England
NG34 8NY
United Kingdom